RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Cartesian Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$6.08−0.19 (-3.03%)
Close on Oct 19, 2026
- Market cap
- $181.55M
- P/E (TTM)
- –
- Dividend yield
- –
Cartesian Therapeutics, Inc. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Operating Segment | $2.80M | $38.91M | – | – | – | – | 100.0% | -92.8% |
| Reporting Segments | – | $38.91M | $26.00M | – | – | – | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Cartesian Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.